PMID- 36045525
OWN - NLM
STAT- MEDLINE
DCOM- 20230519
LR  - 20230519
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 30
IP  - 22
DP  - 2023
TI  - Regulatory Mechanisms of Vanillic Acid in Cardiovascular Diseases: A Review.
PG  - 2562-2576
LID - 10.2174/0929867329666220831152608 [doi]
AB  - Cardiovascular diseases (CVD) are the primary cause of death globally. Activation 
      of oxidative stress and inflammatory pathways are contributory to the development 
      of CVD. Pharmacological activities of vanillic acid have been investigated 
      suggesting that they may have therapeutic utility clinically. Given its phenolic 
      nature, the anti-inflammatory and antioxidant properties of vanillic acid have 
      been shown to exert potent inhibitory activity against Adenosine 
      Monophosphate-Activated Protein Kinase (AMPK), Nuclear Factor Kappa B (NF- kappaB), 
      the Janus kinase (JAK)/signal transducer and activator of transcription (STAT), 
      Nod-like receptor family protein (NLRP), Toll-like receptors (TLRs), 
      Mitogen-Activated Signaling Proteins (MAPK) and Mammalian Target of Rapamycin 
      (mTOR) signaling pathways. Vanillic acid has been shown to block pro-inflammatory 
      cytokines and suppress inflammatory cascades. The inhibitory impact of vanillic 
      acid on reactive oxygen species (ROS) and nitric oxygen synthase (iNOS) 
      expression has also been demonstrated. Vanillic acid reduces oxidative-related 
      markers such as superoxide dismutase (SOD), glutathione (GSH), Heme Oxygenase 1 
      (HO-1), and glutathione peroxidase (GSH-Px). Here, we review the cardioprotective 
      effects and mechanisms of action of vanillic acid in CVD. Current potential 
      applications of vanillic acid in CVD are discussed concerning preclinical and 
      clinical studies.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Lashgari, Naser-Aldin
AU  - Lashgari NA
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
FAU - Roudsari, Nazanin M
AU  - Roudsari NM
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
FAU - Momtaz, Saeideh
AU  - Momtaz S
AD  - Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, 
      Iran.
AD  - Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center 
      (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, 
      Tehran University of Medical Sciences, Tehran, Iran.
AD  - Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran.
FAU - Abdolghaffari, Amir H
AU  - Abdolghaffari AH
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
AD  - Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, 
      Iran.
AD  - Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center 
      (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, 
      Tehran University of Medical Sciences, Tehran, Iran.
AD  - Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific 
      Education and Research Network (USERN), Tehran, Iran.
FAU - Atkin, Stephen L
AU  - Atkin SL
AD  - School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, 
      Busaiteen, Kingdom of Bahrain.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Applied Biomedical Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - School of Medicine, The University of Western Australia, Perth, Australia.
AD  - Department of Biotechnology, School of Pharmacy, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - GM8Q3JM2Y8 (Vanillic Acid)
RN  - 0 (NF-kappa B)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (NF-E2-Related Factor 2)
SB  - IM
MH  - Humans
MH  - *Vanillic Acid/pharmacology/therapeutic use
MH  - *Cardiovascular Diseases/drug therapy
MH  - Signal Transduction
MH  - NF-kappa B/metabolism
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Oxidative Stress
MH  - NF-E2-Related Factor 2/metabolism
OTO - NOTNLM
OT  - Cardiovascular diseases
OT  - atherosclerosis
OT  - cardiomyopathy
OT  - hypertension
OT  - inflammation
OT  - myocardial infarction
OT  - oxidative stress
OT  - vanillic acid
EDAT- 2022/09/02 06:00
MHDA- 2023/05/19 06:42
CRDT- 2022/09/01 01:05
PHST- 2022/01/12 00:00 [received]
PHST- 2022/04/07 00:00 [revised]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2023/05/19 06:42 [medline]
PHST- 2022/09/02 06:00 [pubmed]
PHST- 2022/09/01 01:05 [entrez]
AID - CMC-EPUB-126058 [pii]
AID - 10.2174/0929867329666220831152608 [doi]
PST - ppublish
SO  - Curr Med Chem. 2023;30(22):2562-2576. doi: 10.2174/0929867329666220831152608.